RT Journal Article
SR Electronic
T1 NMR metabolomic modelling of age and lifespan: a multi-cohort analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.07.23298200
DO 10.1101/2023.11.07.23298200
A1 Lau, Chung-Ho E.
A1 Manou, Maria
A1 Markozannes, Georgios
A1 Ala-Korpela, Mika
A1 Shlomo, Yoav Ben-
A1 Chaturvedi, Nish
A1 Engmann, Jorgen
A1 Gentry-Maharaj, Aleksandra
A1 Herzig, Karl-Heinz
A1 Hingorani, Aroon
A1 Järvelin, Marjo-Riitta
A1 Kähönen, Mika
A1 Kivimäki, Mika
A1 Lehtimäki, Terho
A1 Marttila, Saara
A1 Menon, Usha
A1 Munroe, Patricia B.
A1 Palaniswamy, Saranya
A1 Providencia, Rui
A1 Raitakari, Olli
A1 Schmidt, Floriaan
A1 Sebert, Sylvain
A1 Wong, Andrew
A1 Vineis, Paolo
A1 Tzoulaki, Ioanna
A1 Robinson, Oliver
YR 2023
UL http://medrxiv.org/content/early/2023/11/08/2023.11.07.23298200.abstract
AB Metabolomic age models have been proposed for the study of biological aging, however they have not been widely validated. We aimed to assess the performance of newly developed and existing nuclear magnetic resonance spectroscopy (NMR) metabolomic age models for prediction of chronological age (CA), mortality, and age-related disease.98 metabolic variables were measured in blood from nine UK and Finnish cohort studies (N ≈ 31,000 individuals, age range 24-86 years). We used non-linear and penalised regression to model CA and time to all-cause mortality. We examined associations of four new and two previously published metabolomic age models, with ageing risk factors and phenotypes. Within the UK Biobank (N≈ 102,000), we tested prediction of CA, incident disease (cardiovascular disease (CVD), type-2 diabetes mellitus, cancer, dementia, chronic obstructive pulmonary disease) and all-cause mortality.Cross-validated Pearson’s r between metabolomic age models and CA ranged between 0.47–0.65 in the training set (mean absolute error: 8-9 years). Metabolomic age models, adjusted for CA, were associated with C-reactive protein, and inversely associated with glomerular filtration rate. Positively associated risk factors included obesity, diabetes, smoking, and physical inactivity. In UK Biobank, correlations of metabolomic age with chronological age were modest (r = 0.29–0.33), yet all metabolomic model scores predicted mortality (hazard ratios of 1.01 to 1.06 / metabolomic age year) and CVD, after adjustment for CA.While metabolomic age models were only moderately associated with CA in an independent population, they provided additional prediction of morbidity and mortality over CA itself, suggesting their wider applicability.Competing Interest StatementNC serves on, and get personal remuneration for Data Safety and Monitoring Boards for trials sponsored by AstraZeneca. UM reports research collaborations with Intelligent Lab on Fiber, RNA Guardian, Micronoma and MercyBio Analytics.Funding StatementC-H.L and OR are supported by UKRI: MR/S03532X/1; AW and NC are supported by UKRI: MC_UU_00019/1. M.A.-K. was supported by a research grant from the Sigrid Juselius Foundation, the Finnish Foundation for Cardiovascular Research, and the Research Council of Finland (grant no. 357183). J.E. is supported by UKRI/NIHR funded Multimorbidity Mechanism and Therapeutics Research Collaborative (MR/V033867/1). A.H. is supported by the UCL British Heart Foundation Accelerator (AA/18/6/34223), the UCL NIHR Biomedical Research Centre (NIHR203328), the UKRI/NIHR funded Multimorbidity Mechanism and Therapeutics Research Collaborative (MR/V033867/1) and the NIHR Senior Investigator Award NIHR202383. M. Kahonen is supported by the Clinical Chemistry and the Cancer Foundation Finland. M. Kivimaki is supported by the Wellcome Trust (221854/Z/20/Z), Medical Research Council (R024227), National Institute on Aging (R01AG062553, R01AG056477) and Academy of Finland, Finland (350426). UM receives salary support from the MRC CTU at UCL core funding (MR_UU_12023). SS received funding from the Research Council of Finland under grant number 356888. SP is supported by EU H2020, EDCMET Grant no. 825762. The Caerphilly Prospective Study (CaPS) study was undertaken by the former MRC Epidemiology Unit (South Wales) and was funded by the Medical Research Council of the United Kingdom. Phase V data were collected with funding from the Alzheimers Society. NFBC1966 received core support from University of Oulu Grants, 65354, 24000692, Oulu University Hospital Grants 2/97, 8/97, 24301140, ERDF European Regional Development Fund Grant, 539/2010 A31592. The data generation and manpower were also supported by the EU H2020 grants: LongITools (873749), EarlyCause, EDCMET (825762) and the Medical Research Council, UK: MRC/BBSRC MR/S03658X/1 (JPI HDHL H2020). The Young Finns Study has been financially supported by the Academy of Finland: grants 356405, 322098, 286284, 134309 (Eye), 126925, 121584, 124282, 255381, 256474, 283115, 319060, 320297, 314389, 338395, 330809, and 104821, 129378 (Salve), 117797 (Gendi), and 141071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research ; Finnish Cultural Foundation; The Sigrid Juselius Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjo Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; EU Horizon 2020 (grant 755320 for TAXINOMISIS and grant 848146 for To Aition); European Research Council (grant 742927 for MULTIEPIGEN project); Tampere University Hospital Supporting Foundation, Finnish Society of Clinical Chemistry and the Cancer Foundation Finland. SABRE was supported at baseline by the Medical Research Council, Diabetes UK and the British Heart Foundation. At follow-up the study was funded by the Wellcome Trust [grant numbers 067100, 37055891 and 086676/7/08/Z], the British Heart Foundation [grant numbers PG/06/145, PG/08/103/26133, PG/12/ 29/29497 and CS/13/1/30327] and Diabetes UK [grant number 13/ 0004774]. UKCTOCS was funded by Medical Research Council (G9901012 and G0801228), CRUK (C1479/A2884), and the Department of Health, with additional support from The Eve Appeal. The UK Medical Research Council and Wellcome (Grant ref:217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and Oliver Robinson will serve as guarantors for the contents of this paper Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for each cohort study was obtained from the Local Research Ethics Committees. Additionally, the current study was approved by the Imperial College Research Ethics Committee (Reference: 19IC5567).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available upon application to steering committee of each cohort.NMRnuclear magnetic resonanceMAEmean absolute errorCIconfidence intervalFDRfalse discovery rateMARSmultivariate adaptive regression splinesVIFvariable inflation factorVIPvariable importance of projectionCVDcardiovascular diseaseCOPDchronic obstructive pulmonary diseaseCAchronological ageBMIBody Mass IndexApoBApolipoprotein BHDLhigh-density lipoproteinVLDLvery low-density lipoproteinLDLlow-density lipoproteinIDLintermediate-density lipoproteinTGtriglyceridesDHAdocosahexaenoic acidSBPsystolic blood pressureDBPdiastolic blood pressureCRPC-reactive proteineGFRestimated glomerular filtration rateFEV1forced expiratory volume in first secondUKBUK BiobankSABRESouthhall and Brent RevisitedBWHHSBritish Women’s Health Heart StudyUKCTOCSThe Collaborative UK Ovarian Cancer Screening TrialWHIIWhitehall IINSHDMRC National Survey of Health and DevelopmentYFSYoung Finns StudyNFBC1966The 1966 Northern Finland Birth CohortCAPSCaerphilly Prospective StudyALSPACAvon Longitudinal Study of Parents and ChildrenUCLEBUCL-LSHTM-Edinburgh-Bristol Consortium